A phase II pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis.
MD Anderson Study Status
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.